Eli Lilly and Company

CompanyUnited StatesFounded 1875

ROROpenAlexWikidata

Eli Lilly and Company develops 103 assets, the furthest approved (abemaciclib in Advanced or Metastatic Breast Cancer). Mostly small molecule and antibody acting on GLP1R, ESR1 and INSR; based in the United States, founded in 1875.

103
Assets
Furthest stage
Approved
2
Grants
1,476
Trials
989
Signals

Pipeline

103
  • abemaciclib

    Inhibits CDK4 and CDK6 to block cell cycle progression and cancer cell proliferation.

    Approved, Small molecule, CDK6, CDK4, Advanced or Metastatic Breast Cancer, early breast cancer

  • Adcirca

    Approved, PDE5A, pulmonary arterial hypertension, benign prostatic hyperplasia (Phase 3)

  • baricitinib

    Selective JAK1 and JAK2 inhibitor that reduces inflammatory signaling pathways.

    Approved, Small molecule, JAK2, JAK1, Active Rheumatoid Arthritis, rheumatoid arthritis

100 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

12

In the full profile

  • Evidence behind the mechanisms12
  • Trials1,992
  • Deals12
  • Signals20
  • Integrity notices3
  • Similar companies6

Papers

Intelligence